Cover Image
市場調查報告書

MK-1602(偏頭痛治療藥):市場預測與分析

MK-1602 (Migraine) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 301159
出版日期 內容資訊 英文 56 Pages
訂單完成後即時交付
價格
Back to Top
MK-1602(偏頭痛治療藥):市場預測與分析 MK-1602 (Migraine) - Forecast and Market Analysis to 2023
出版日期: 2014年03月31日 內容資訊: 英文 56 Pages
簡介

Merck目前開發中的MK-1602是CGRP(抑鈣素基因系胜肽)受體抑制劑的一種,是被稱為gepant,新類偏頭痛緊急治療的一種。CGRP是血管活性神經肽,其受體分佈於末端、中樞神經系統整體(三叉神經血管複合體,視丘,視丘下部,三叉神經節等)(Hoffmann and Goadsby, 2012)。根據許多病例指出,CGRP是偏頭痛病理學上主要的媒介物質。

本報告提供偏頭痛的治療藥之一──MK-1602的全球市場相關分析,提供偏頭痛概要和治療方法,競爭的企業·藥品概要,市場競爭概況,MK-1602商品資訊(特色·功效·安全性等),全球主要國家的市場販售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 本報告概要
  • 相關調查
  • 近日出版的相關調查

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理生理學
    • 預測
  • 症狀
    • 前驅症狀階段
    • 前兆階段
    • 疼痛的階段
    • 後發症狀的階段

第4章 疾病管理

  • 治療方法概要
    • 急性偏頭痛的治療
    • 偏頭痛的預防療法

第5章 競爭企業的評估

  • 概要
  • 競爭企業的策略性評估

第6章 市場機會及未滿足需求

  • 概要
    • 缺乏具有心血管疾病風險的患者的緊急治療方式
    • 缺乏Triptan療法無效的患者的緊急治療方式
    • 缺乏診斷工具造成的誤診
    • 醫生教育
    • 有效有耐容性的預防療法
  • 未滿足需求的差距分析
    • 具有心血管疾病風險的患者,及Triptan療法無效的患者的緊急治療
    • 有效有耐容性(針對偏頭痛)預防療法
    • 醫生教育
    • 診斷工具

第7章 開發平台評估

  • 概要
  • 臨床實驗中的有潛力的藥劑

第8章 關於MK-1602

  • 概要
  • 功效
  • 安全性
  • 給藥·劑型方法
  • 在臨床方面的潛在性地位
  • 在商業方面的潛在性地位
  • 價格設定和醫療費給付
  • SWOT分析
  • 未來預測

第9章 附錄

圖表一覽

目錄
Product Code: GDHC384DFR

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

MK-1602, under development by Merck, is a calcitonin gene-related peptide (CGRP) receptor antagonist. It is a member of a new class of therapy for the acute treatment of migraine, called the gepants. CGRP is a vasoactive neuropeptide whose receptors are widely distributed in the peripheral and central nervous systems such as the trigeminovascular complex, thalamus, hypothalamus and trigeminal ganglion (Hoffmann and Goadsby, 2012). CGRP has been indicated as a key mediator of migraine pathology by several lines of evidence.

Scope

  • Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on MK-1602 including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for MK-1602 for the top seven countries from 2012 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Migraine
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of MK-1602 performance
  • Obtain sales forecast for MK-1602 from 2012-2023 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
  • 3.2. Symptoms
    • 3.2.1. Premonitory Phase
    • 3.2.2. Aura Phase
    • 3.2.3. Headache Phase
    • 3.2.4. Postdrome Phase

4. Disease Management

  • 4.1. Treatment Overview
    • 4.1.1. Acute Migraine Treatment
    • 4.1.2. Preventive Migraine Treatment

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Opportunity and Unmet Need

  • 6.1. Overview
    • 6.1.1. A Lack of Acute Therapies for Patients with or at Risk of Cardiovascular Disorders
    • 6.1.2. Lack of Acute Therapies for Patients Unresponsive to Triptan Medication
    • 6.1.3. Lack of Diagnostic Tools Causes Misdiagnosis
    • 6.1.4. Physician Education
    • 6.1.5. Effective and Well-Tolerated Prophylactic Therapies
  • 6.2. Unmet Needs Gap Analysis
    • 6.2.1. Acute Therapies for Patients with or at Risk of Cardiovascular Disorders and for Patients Unresponsive to Triptan Medication
    • 6.2.2. Effective and Well-Tolerated (Migraine-Specific) Preventive Therapies
    • 6.2.3. Physician Education
    • 6.2.4. Diagnostic Tools

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising drugs in clinical development

8. MK-1602

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement
  • 8.8. SWOT Analysis
  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Migraine Patients
    • 9.4.2. Percent Drug-treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Survey of Prescribing Physicians
  • 9.7. About the Authors
    • 9.7.1. Author
    • 9.7.2. Reviewer
    • 9.7.3. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Classification of Migraine Subtypes
  • Table 2: Diagnostic Criteria for Migraine with Aura
  • Table 3: Diagnostic Criteria for Migraine without Aura
  • Table 4: Treatment Guidelines for Migraine
  • Table 5: Most Prescribed Drugs for Migraine by Class in the Major Markets, 2013
  • Table 6: Overall Unmet Needs - Current Level of Attainment
  • Table 7: Clinical Unmet Needs - Gap Analysis, 2013
  • Table 8: Migraine - Promising Late-Stage Pipeline, 2013
  • Table 9: Comparison of Therapeutic Classes in Development for Migraine, 2013
  • Table 10: Product Profile - MK-1602
  • Table 11: MK-1602 SWOT Analysis, 2013
  • Table 12: Global Sales Forecasts ($m) for MK-1602, 2012-2023
  • Table 13: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Migraine Treatment Algorithm in the 7MM
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Migraine, 2012-2023
Back to Top